Lewis Mervin obtained his PhD from the University of Cambridge in 2017 through a BBSRC/AstraZeneca CASE studentship, working on the development of novel algorithms for mode-of-action analysis. He spent two years as a postdoctoral researcher studying the systems biology of alcohol addiction (Sybil-AA) and was co-founder/head of technology at PharmEnable (accessing novel chemical space for difficult targets). In 2019, Lewis joined AstraZeneca, UK, as a machine learning and cheminformatics expert in computational chemistry.